Karyotype of Leukemia Cells Consistently Predicts for Response to Therapy and Survival Following Salvage Therapy in Acute Myeloblastic Leukemia

  • M. J. Keating
  • H. Kantarjian
  • E. Estey
  • W. Plunkett
  • J. Trujillo
  • K. B. McCredie
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)

Abstract

Following the introduction of anthracyclines and cytosine arabinoside (Ara-C) into clinical practice in the late 1960s, response rates of 50%–80% in previously untreated patients with acute myeloblasts leukemia (AML) have been obtained [1, 2]. Despite a variety of postremission treatments the remission duration remains 12–15 months, with 20%–25% of patients staying in long-term disease-free state and possibly being cured [3, 4]. One-third of the patients who failed to achieve an initial complete remission do so because of persistence of leukemia cells [5], and 75%–80% of patients who achieve a remission have recurrence of leukemia [3, 4]. Both of these patient populations are eligible for salvage therapy.

Keywords

Leukemia Prednisone Fibrinogen Dura Anthracyclines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Keating MJ, Smith TL, McCredie KB, Bodey GP, Hersh EM, Gutterman JU, Gehan EA, Freireich EJ (1981) A four-year experience with anthracycline, cytosine arabinoside, vincristine, and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47: 2779 - 2788PubMedCrossRefGoogle Scholar
  2. 2.
    Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawahi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, Ellison RR, Kung F, Henry P, Mclntyre OR, Kaan SK (1981) Treatment of myelocytic leukaemia. A study by Cancer and Leukaemia Group B. Blood 58: 1203-1212Google Scholar
  3. 3.
    Keating MJ, Bodey GP, McCredie KB, Smith TL, Gehan EA, Youness E, Trujillo JM, Freireich EJ (1982) Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 248: 2481 - 2486PubMedCrossRefGoogle Scholar
  4. 4.
    Weinstein HM, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD (1983) Chemotherapy for acute myelogenous leukemia in children and adults. VAPA update. Blood 62: 315-319Google Scholar
  5. 5.
    Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1982) Causes of initial remission induction failure in acute myelogenous leukemia. Blood 60: 309 - 315PubMedGoogle Scholar
  6. 6.
    Legha SS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1982) Evaluation of AMSA in previously treated patients with leukemia: results of therapy in 109 adults. Blood 60: 484 - 490PubMedGoogle Scholar
  7. 7.
    Arlin ZA, Sklaroff RB, Gee TS, Kempin SJ, Howard J, Clarkson BD (1980) Phase I and II trial of 4,-(-acridinylamino)methane-sulfon-manisidide in patients with acute leukemia. Cancer Res 40: 3304 - 3306PubMedGoogle Scholar
  8. 8.
    Arlin ZA, Dukart G, Schoch I, Reisman A, Moore J, Silver RA, Cassileth P, Bertino J, Gams R (1985) Phase I—II trial of mitoxantrone in acute leukemia: an interim report. Invest New Drugs 3: 213 - 217PubMedCrossRefGoogle Scholar
  9. 9.
    Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1983) Phase II trial of mi-toxantrone in acute leukemia. Cancer Treat Rep 67: 389 - 390PubMedGoogle Scholar
  10. 10.
    Benjamin RS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1977) Phase I-II trial of rubidazone in patients with acute leukemia. Cancer Res 37: 4223 - 4228Google Scholar
  11. 11.
    Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW (1985) Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin ( Idarubicin) in adult patients with acute leukemia. Cancer Res 45: 1408-1412Google Scholar
  12. 12.
    Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters RS, Kantarjian HM; Andersson BS, Beran M, McCredie KB, Freireich EJ (1985) Evolution of clinical studies with high-dose cytosine arabinoside at the M. D. Anderson Hospital. Semin Oncol 12: 98-104Google Scholar
  13. 13.
    Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, Mcintosh S (1979) High dose cytosine arabinoside ( HDARAC) in refractory acute leukemia. Cancer 44: 1189-1193Google Scholar
  14. 14.
    Herzig RH, Wolff SN, Lazarus HM, Philips GL, Karanes C, Herzig GP (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62: 361 - 369PubMedGoogle Scholar
  15. 15.
    Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Buchner T (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69: 744 – 749PubMedGoogle Scholar
  16. 16.
    Bennett JM, Lymann GH, Cassileth PA, Glick JH, Oken MM (1984) A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group Study. Am J Clin Oncol 7: 471-473Google Scholar
  17. 17.
    Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T, McCredie KB, Freireich EJ (1987) Comparison of salvage therapy in adult acute myelogenous leukemia. Proc Second Int Conf Catania, 1986. Acta Haematol (Basel) 78 [Suppl 1]: 120 - 126CrossRefGoogle Scholar
  18. 18.
    Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ (1988) Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2: 403 - 412PubMedGoogle Scholar
  19. 19.
    Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7: 1071 - 1080PubMedGoogle Scholar
  20. 20.
    Smith TL, Gehan EA, Keating MJ, Freireich EJ (1982) Prediction of remission in adult acute leukemia. Development and testing of predictive models. Cancer 50: 466-471Google Scholar
  21. 21.
    Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR (1989) Prognostic impact of cy-togenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73: 263 - 270PubMedGoogle Scholar
  22. 22.
    Samuels BL, Larson RA, LeBeau MM, Daly KM, Bitter MA, Vardiman JW, Barker CM, Rowley JD, Golomb HM (1988) Specific chromosomal abnormalities in acute non-lymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 2: 79 - 83PubMedGoogle Scholar
  23. 23.
    Estey R, Smith TL, Keating MJ, McCredie KB, Gehan EA, Freireich EJ (1989) Predicition of survival during induction therapy in patients with newly-diagnosed acute myeloblasts leukemia. Leukemia 3: 257 - 263PubMedGoogle Scholar
  24. 24.
    Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ (1987) A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol 5: 710 - 721PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • M. J. Keating
    • 1
  • H. Kantarjian
    • 1
  • E. Estey
    • 1
  • W. Plunkett
    • 1
  • J. Trujillo
    • 1
  • K. B. McCredie
    • 1
  1. 1.Departments of Hematology and Pharmacology, Division of Medicine, and Laboratory MedicineUniversity of Texas, M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations